[HTML][HTML] Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH …
KA Martin, J Beyer‐Westendorf, BL Davidson… - Journal of thrombosis …, 2021 - Elsevier
Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes
T Zhang, EHJ Krekels, C Smit… - Expert opinion on drug …, 2022 - Taylor & Francis
Introduction Obesity is associated with many physiological changes. We review available
evidence regarding five commonly accepted assumptions to a priori predict the impact of …
evidence regarding five commonly accepted assumptions to a priori predict the impact of …
Oral anticoagulants beyond warfarin
RH Olie, K Winckers, B Rocca… - Annual Review of …, 2024 - annualreviews.org
Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …
Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study
AC Martin, W Thomas, Z Mahir… - Thrombosis and …, 2021 - thieme-connect.com
Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and
venous thromboembolism (VTE) and both occur more frequently in obese patients …
venous thromboembolism (VTE) and both occur more frequently in obese patients …
Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review
Older adults, the fastest growing population, represent almost 50% of all users of direct oral
anticoagulants (DOACs). Unfortunately, we have very little relevant pharmacological and …
anticoagulants (DOACs). Unfortunately, we have very little relevant pharmacological and …
[HTML][HTML] Monitoring of anticoagulation in thrombotic antiphospholipid syndrome
H Cohen, M Efthymiou, KMJ Devreese - Journal of Thrombosis and …, 2021 - Elsevier
Anticoagulation is central to the management of thrombotic antiphospholipid syndrome
(APS). The standard anticoagulant treatment for thrombotic APS is life‐long warfarin or an …
(APS). The standard anticoagulant treatment for thrombotic APS is life‐long warfarin or an …
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes
A Ballerie, RN Van, K Lacut, H Galinat, C Rousseau… - Thrombosis research, 2021 - Elsevier
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
Is a lower dose of rivaroxaban required for Asians? A systematic review of a population pharmacokinetics and pharmacodynamics analysis of rivaroxaban
XQ Liu, ZR Li, CY Wang, YT Chen, Z Jiao - Pharmaceutics, 2023 - mdpi.com
Rivaroxaban has been widely used to prevent and treat various thromboembolic diseases
for more than a decade. However, whether a lower dose of rivaroxaban is required for …
for more than a decade. However, whether a lower dose of rivaroxaban is required for …
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - mdpi.com
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …